Identification and Analysis of the Physiological Ligand for TLT2

TLT2生理配体的鉴定与分析

基本信息

  • 批准号:
    8568235
  • 负责人:
  • 金额:
    $ 20.7万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-05-22 至 2015-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The goal of this proposal is to elucidate the physiological expression pattern of the ligand for TLT2 in response to acute inflammation. This information will be used to generate a subtracted cDNA library to clone the gene encoding the ligand for TLT2. TLT2 is a transmembrane receptor that is expressed on neutrophils, monocytes/macrophages and B cells. Studies have demonstrated that TLT2 ligation potentiates the response of neutrophils to agonists that bind to G protein coupled receptors leading to enhanced ROS production, degranulation and chemotaxis. TLT2 expression is upregulated on neutrophils and macrophages in response to inflammation and potentiates neutrophil recruitment to sites of inflammation in vivo. Additionally, TLT2 ligation in vivo leads to the production of G-CSF and the chemokines KC and MIP-2. These factors act on neutrophils to increase their mobilization from the bone marrow and to direct their migration to sites of infection or inflammation. Thus, studies demonstrate that TLT2 drives a positive feed-forward loop that involves the production of factors that modulate neutrophil activation and chemotaxis, and at the same time potentiates the neutrophil response to those factors (i.e. KC and MIP-2). These findings support the hypothesis that TLT2 plays an important role in regulating the innate immune response to microbial challenge. At the same time, TLT2 may drive processes that contribute to the acute inflammatory response. Manipulation of TLT2- dependent processes in vivo provides direct support for both hypotheses. Intravenous administration of agonistic anti-TLT2 mAb protects mice from a lethal intratracheal challenge with S. pneumonia. Conversely, intravenous administration of blocking TLT2:Fc recombinant fusion protein attenuates recruitment of neutrophils to the lung in response to intratracheal administration of LPS. Thus, TLT2 serves an important, non-redundant role in regulating the innate immune response. To more fully appreciate the physiological role of TLT2 during the innate immune response, it is critical to identify the ligand for TLT2. Towards this goal, experiments are proposed to analyze TLT2 ligand expression in response to acute inflammation (Specific Aim 1). These studies are designed to demonstrate that TLT2 ligand expression is upregulated in a spatial and temporal manner in response to inflammation. Subsequent studies will utilize this information to generate subtracted cDNA libraries to be used in expression cloning to identify the gene that encodes the TLT2 ligand (Specific Aim 2). The information obtained will significantly extend understanding of molecular processes that control the innate immune response and will identify a novel target (i.e. the TLT2 ligand) for the development of therapeutic interventions to modulate the acute inflammatory response.
描述(由申请人提供):本提案的目的是阐明TLT 2配体在急性炎症反应中的生理表达模式。该信息将用于产生消减cDNA文库以克隆编码TLT 2配体的基因。TLT 2是在中性粒细胞、单核细胞/巨噬细胞和B细胞上表达的跨膜受体。研究表明,TLT 2连接增强了嗜中性粒细胞对结合G蛋白偶联受体的激动剂的反应,导致ROS产生、脱粒和趋化性增强。TLT 2表达在中性粒细胞和巨噬细胞上响应于炎症而上调,并增强中性粒细胞向体内炎症部位的募集。此外,体内TLT 2连接导致G-CSF和趋化因子KC和MIP-2的产生。这些因子作用于中性粒细胞,以增加其从骨髓的动员,并引导其迁移到感染或炎症部位。因此,研究表明,TLT 2驱动正前馈回路,其涉及调节中性粒细胞活化和趋化性的因子的产生,并且同时增强中性粒细胞对这些因子(即KC和MIP-2)的应答。这些发现支持了TLT 2在调节对微生物挑战的先天免疫应答中起重要作用的假设。与此同时,TLT 2可能驱动导致急性炎症反应的过程。TLT 2依赖性过程在体内的操纵为这两种假设提供了直接支持。静脉内给予激动性抗TLT 2 mAb可保护小鼠免受S.肺炎相反,静脉内施用阻断性TLT 2:Fc重组融合蛋白减弱了响应于LPS的气管内施用的嗜中性粒细胞向肺的募集。因此,TLT 2在调节先天免疫应答中起重要的、非冗余的作用。为了更充分地了解TLT 2在先天免疫应答期间的生理作用,鉴定TLT 2的配体是至关重要的。为了实现这一目标,提出了实验来分析响应于急性炎症的TLT 2配体表达(具体目标1)。这些研究旨在证明TLT 2配体表达在炎症反应中以空间和时间方式上调。后续研究将利用该信息生成用于表达克隆的消减cDNA文库,以鉴定编码TLT 2配体的基因(特异性目的2)。所获得的信息将显著扩展对控制先天免疫应答的分子过程的理解,并将鉴定用于开发调节急性炎症应答的治疗干预的新靶点(即TLT 2配体)。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LOUIS B JUSTEMENT其他文献

LOUIS B JUSTEMENT的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LOUIS B JUSTEMENT', 18)}}的其他基金

CD19 Tyrosine-mediated Signal Transduction in vivo
CD19 酪氨酸介导的体内信号转导
  • 批准号:
    8081969
  • 财政年份:
    2010
  • 资助金额:
    $ 20.7万
  • 项目类别:
Regulation of B Lymphocyte Survival and Differentiation by HSH2
HSH2 对 B 淋巴细胞存活和分化的调节
  • 批准号:
    7612425
  • 财政年份:
    2008
  • 资助金额:
    $ 20.7万
  • 项目类别:
Regulation of B Lymphocyte Survival and Differentiation by HSH2
HSH2 对 B 淋巴细胞存活和分化的调节
  • 批准号:
    7367189
  • 财政年份:
    2007
  • 资助金额:
    $ 20.7万
  • 项目类别:
Regulation of B Lymphocyte Survival and Differentiation by HSH2
HSH2 对 B 淋巴细胞存活和分化的调节
  • 批准号:
    7191849
  • 财政年份:
    2007
  • 资助金额:
    $ 20.7万
  • 项目类别:
Regulation of B Lymphocyte Survival and Differentiation by HSH2
HSH2 对 B 淋巴细胞存活和分化的调节
  • 批准号:
    8030421
  • 财政年份:
    2007
  • 资助金额:
    $ 20.7万
  • 项目类别:
Regulation of B Lymphocyte Survival and Differentiation by HSH2
HSH2 对 B 淋巴细胞存活和分化的调节
  • 批准号:
    7586201
  • 财政年份:
    2007
  • 资助金额:
    $ 20.7万
  • 项目类别:
Regulation of B Lymphocyte Survival and Differentiation by HSH2
HSH2 对 B 淋巴细胞存活和分化的调节
  • 批准号:
    7775050
  • 财政年份:
    2007
  • 资助金额:
    $ 20.7万
  • 项目类别:
CD19 Tyrosine-mediated Signal Transduction in vivo
CD19 酪氨酸介导的体内信号转导
  • 批准号:
    7647892
  • 财政年份:
    1998
  • 资助金额:
    $ 20.7万
  • 项目类别:
CD19 Tyrosine-mediated Signal Transduction in vivo
CD19 酪氨酸介导的体内信号转导
  • 批准号:
    7533208
  • 财政年份:
    1998
  • 资助金额:
    $ 20.7万
  • 项目类别:
CD19 Tyrosine-mediated Signal Transduction in vivo
CD19 酪氨酸介导的体内信号转导
  • 批准号:
    8289609
  • 财政年份:
    1998
  • 资助金额:
    $ 20.7万
  • 项目类别:

相似海外基金

Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
  • 批准号:
    10648387
  • 财政年份:
    2023
  • 资助金额:
    $ 20.7万
  • 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
  • 批准号:
    10591804
  • 财政年份:
    2023
  • 资助金额:
    $ 20.7万
  • 项目类别:
MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION
MAP2K1 和 MAP2K2 在急性肺损伤中的作用及缓解
  • 批准号:
    10741574
  • 财政年份:
    2023
  • 资助金额:
    $ 20.7万
  • 项目类别:
Lung epithelial cell-derived C3 in acute lung injury
肺上皮细胞衍生的 C3 在急性肺损伤中的作用
  • 批准号:
    10720687
  • 财政年份:
    2023
  • 资助金额:
    $ 20.7万
  • 项目类别:
Examining the role of TRMT1 and tRNA methylation in acute lung injury and ARDS
检查 TRMT1 和 tRNA 甲基化在急性肺损伤和 ARDS 中的作用
  • 批准号:
    10719249
  • 财政年份:
    2023
  • 资助金额:
    $ 20.7万
  • 项目类别:
Development of a new treatment for COVID-19-related acute lung injury targeting the microbiota-derived peptide corisin
针对微生物群衍生肽 corisin 开发治疗 COVID-19 相关急性肺损伤的新疗法
  • 批准号:
    23K07651
  • 财政年份:
    2023
  • 资助金额:
    $ 20.7万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Probing immunovascular mechanobiology in pneumonia-associated acute lung injury at the single capillary level
在单毛细血管水平探讨肺炎相关急性肺损伤的免疫血管力学生物学
  • 批准号:
    10679944
  • 财政年份:
    2023
  • 资助金额:
    $ 20.7万
  • 项目类别:
The amyloid precursor protein protects against acute lung injury
淀粉样前体蛋白可预防急性肺损伤
  • 批准号:
    10575258
  • 财政年份:
    2023
  • 资助金额:
    $ 20.7万
  • 项目类别:
Role of macrophages and miRNA in regulating lung macrophage polarization and lung pathogenesis during respiratory virus-induced acute lung injury in normal and diabetic Syrian hamsters.
正常和糖尿病叙利亚仓鼠呼吸道病毒引起的急性肺损伤期间巨噬细胞和 miRNA 在调节肺巨噬细胞极化和肺部发病机制中的作用。
  • 批准号:
    10701207
  • 财政年份:
    2023
  • 资助金额:
    $ 20.7万
  • 项目类别:
Roles of N-glycans on neutrophil beta2 integrins in progression of acute lung injury
N-聚糖对中性粒细胞β2整合素在急性肺损伤进展中的作用
  • 批准号:
    10837431
  • 财政年份:
    2023
  • 资助金额:
    $ 20.7万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了